Company profile

Covagen AG (acquired by Cilag GmbH International)

Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.

More news about Covagen AG (acquired by Cilag GmbH International)

17.04.2015 11:52

Nine hot start-ups, 400 visitors and Joe Jimenez

Please login or
register to use the
awards follow feature
25.08.2014 16:44

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Please login or
register to use the
awards follow feature
05.05.2014 10:24

Covagen’s first clinical trials

Please login or
register to use the
awards follow feature
19.02.2014 14:57

Covagen Adds Baxter Ventures as Investor

Please login or
register to use the
awards follow feature
09.12.2013 18:05

Covagen Secures CHF 42 Million in Series B Financing

Please login or
register to use the
awards follow feature
21.11.2013 16:28

Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration

Please login or
register to use the
awards follow feature
15.04.2013 09:56

Covagen hires experienced Chief Business Officer

Please login or
register to use the
awards follow feature
18.10.2012 12:51

Covagen enters into a partnership and gets EUR 4 million upfront payment

Please login or
register to use the
awards follow feature
04.01.2012 15:19

Important step for Covagen

Please login or
register to use the
awards follow feature
Covagen AG (acquired by Cilag GmbH International)

Founded
2007

Kanton
ZH

Homepage

rss